Liang Cheng, Director of Anatomic Pathology and Director of Molecular Pathology at Lifespan Academic Medical Center and Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University, shared a post on X about a paper he co-authored with colleagues published in European Urology Focus:
“I am delighted to share that our paper, ‘Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management,’ has just been published in the latest issue of European Urology Focus.
Congratulations to Joanne and our esteemed colleagues!
Urinary tumor DNA (utDNA) shows strong potential to improve nearly all stages of bladder cancer detection, treatment, and monitoring.
It maintains the low cost and noninvasiveness of urine cytology while offering accuracy that rivals or exceeds – cystoscopy and circulating tumor DNA (ctDNA) – based methods.
Its superior sensitivity enables detection of both low-grade tumors and early recurrences, supporting better treatment planning and outcomes.
utDNA also offers insights into tumor grade, stage, prognosis, and minimal residual disease, with advantages that merit further exploration beyond bladder cancer.
Future studies should compare standalone utDNA approaches with combined strategies and evaluate integration with AI-driven tools to advance bladder cancer care.”
Title: Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review
Authors: Joanne Lee, Fei Chen, Antonio Lopez-Beltran, Andrea Necchi, Alessia Cimadamore, Philippe E. Spiess, Roger Li, Sinchita Roy-Chowdhuri, Rodolfo Montironi, Dragan Golijanin, Claudio Luchini, Liang Cheng
You can read the full article in European Urology Focus.
More posts featuring Bladder Cancer.